Professor Kandalaft holds a Doctorate in Pharmacy and a Ph.D. from the Welsh School of Pharmacy at Cardiff University, UK, and a Master’s Degree in Translational Research from the University of Pennsylvania, USA. She completed her postdoctoral fellowship training at The National Cancer Institute, Bethesda, Maryland, focusing on preclinical animal models and cancer therapeutics.
Professor Kandalaft is a key member of the Swiss Cancer Center in Lausanne Switzerland. She is currently Cheffe de Service (Director) of the Center of Experimental Therapeutics in the Department of Oncology, at the CHUV and the Swiss Cancer Center Lausanne, Switzerland.
Professor Kandalaft has strong expertise in clinical development, regulatory policies and translational research. She is interested in translational cell-based cancer immunotherapy with a special focus on developing personalized cancer vaccines.